Home > Insider Trading > Filing (0001209191-17-065406)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1503802	Karyopharm Therapeutics Inc.	KPTI	Pharmaceutical Preparations (2834)	263931704

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1603510	Brett Christopher Primiano	C/O Karyopharm Therapeutics Inc. 85 Wells Avenue Newton MA 02459	Svp, Ops, Bus Dev, Gc & Sec	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2017-12-11	10,042	$10.88	11,381	No	4	S	Direct
Common Stock	Acquisiton	2017-12-12	17,000	$6.54	28,381	No	4	M	Direct
Common Stock	Disposition	2017-12-12	16,356	$9.93	12,025	No	4	S	Direct
Common Stock	Disposition	2017-12-12	644	$9.59	11,381	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2017-12-12	17,000	$0.00	17,000	$6.54

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
23,000		2026-01-16	No	4	M	Direct

Footnotes

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.68 to $11.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.60 to $10.59, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average sale price. These shares were sold in multiple transactions at $9.56 and $9.59. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 15, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.